Chromogranin-A levels measured with automated immunoassay

International Journal of Biological Markers

Volumn 30, Issue 1, 2015, Pages e132-e135

  Gruson, Damien ^a   Lepoutre, Thibault ^a   Smits, Françoise ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b PFIZER INC   (United States)

Author keywords

Chromogranin; Heart failure; Immunoassay; Neuroendocrine

Indexed keywords

CHROMOGRANIN A; BIOLOGICAL MARKER;

ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; NEUROENDOCRINE TUMOR; BLOOD; BLOOD ANALYSIS; LIMIT OF DETECTION; PROCEDURES; REFERENCE VALUE; STANDARDS;

BIOMARKERS; BLOOD CHEMICAL ANALYSIS; CHROMOGRANIN A; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIMIT OF DETECTION; REFERENCE VALUES;

EID: 84930068971     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000096     Document Type: Article

References (13)

1. Tota B, Angelone T, Mazza R, Cerra MC. The chromogranin A-derived vasostatins: new players in the endocrine heart. Curr Med Chem. 2008; 15(14): 1444-1451.
2. Ramachandran R, Bech P, Murphy KG, et al. Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays. Clin Endocrinol (Oxf). 2012; 76(6): 831-836.
3. Molina R, Alvarez E, Aniel-Quiroga A, et al. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies. Tumour Biol. 2011; 32(1): 13-22.
4. Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol. 2003; 177(2): 337-341.
5. Popovici T, Moreira B, Schlageter MH, Bories PN. Automated two-site immunofluorescent assay for the measurement of serum chromogranin A. Clin Biochem. 2014; 47(1-2): 87-91.
6. Dittadi R, Bertoli I. Evaluation of an ELISA method for the measurement of chromogranin A and comparison with an immunoradiometric method. Int J Biol Markers. 2013; 28(1): 114-116.
7. Leon A, Torta M, Dittadi R, et al. Comparison between two methods in the determination of circulating chromogranin A in neuroendocrine tumors (NETs): results of a prospective multicenter observational study. Int J Biol Markers. 2005; 20(3): 156-168.
8. Di Comite G, Morganti A. Chromogranin A: a novel factor acting at the cross road between the neuroendocrine and the cardiovascular systems. J Hypertens. 2011; 29(3): 409-414.
9. Mazza R, Imbrogno S, Tota B. The interplay between chromogranin A-derived peptides and cardiac natriuretic peptides in cardioprotection against catecholamine-evoked stress. Regul Pept. 2010; 165(1): 86-94.
10. Tota B, Angelone T, Mazza R, Cerra MC. The chromogranin A-derived vasostatins: new players in the endocrine heart. Curr Med Chem. 2008; 15(14): 1444-1451.
11. Angelone T, Mazza R, Cerra MC. Chromogranin-A: a multifaceted cardiovascular role in health and disease. Curr Med Chem. 2012; 19(24): 4042-4050.
12. Ceconi C, Ferrari R, Bachetti T, et al. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J. 2002; 23(12): 967-974.
13. Dieplinger B, Gegenhuber A, Struck J, et al. Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure. Clin Chim Acta. 2009; 400(1-2): 91-96.